IP Library › Granted Patent US 10,513,738
Granted Patent B2
US 10,513,738 · App. 15/328,733 · Granted Dec 24, 2019

Method to diagnose malignant melanoma in the domestic dog

Inventor: Matthew Breen (Raleigh, NC)
Assignee: North Carolina State University
C12Q1/6886G01N33/5743C12Q2600/124C12Q2600/156C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,513,738
App. No.
15/328,733
Granted
Dec 24, 2019
Kind
B2
Abstract

This disclosure is directed to the discovery of an improved method to diagnose malignant melanoma of the oral cavity in the dog.

Claims (19)

1. A method for detecting and treating a canine malignant oral melanoma, the method comprising:

(a) measuring copy numbers of CFA 10:5, CFA 10:14, CFA 10:20, CFA 30:9, and CFA 30:19 in a biological sample from a dog, wherein:

(i) the biological sample comprises cancer cells isolated from the oral cavity of the dog and/or DNA isolated therefrom; and

(ii) the copy numbers of CFA 10:5, CFA 10:14, CFA 10:20, CFA 30:9, and CFA 30:19 are measured by aberrations at CFA chr10:1617000-2513700, CFA chr10:10887000-11116000, CFA chr10:17366629-17720225, CFA chr30:5300000-6000000, and CFA chr30:15500000-18000000 from camfam3, respectively;

(b) detecting increased copy numbers of CFA 10:5, CFA 10:14, and CFA 30:19 and reduced copy numbers of CFA 10:20 and CFA 30:9 compared to a normal control in the biological sample;

(c) diagnosing the dog with malignant oral melanoma; and

(d) treating the malignant oral melanoma in the dog with surgical resection, radiation therapy, an anti-melanoma vaccine, chemotherapy, or any combination thereof.

2. The method of claim 1 , wherein the copy numbers of CFA 10:5, CFA 10:14, and CFA 30:19 are >2.0.

3. The method of claim 1 , wherein the copy numbers of CFA 10:20 and CFA 30:9 are <2.0.

4. The method of claim 1 , wherein both the copy numbers of CFA 10:5, CFA 10:14, and CFA 30:19 are >2.0 and the copy numbers of CFA 10:20 and CFA 30:9 are <2.0.

5. The method of claim 1 , wherein the copy numbers are measured by fluorescence in situ hybridization (FISH).

6. The method of claim 1 , wherein the copy numbers are measured by polymerase chain reaction (PCR).

7. The method of claim 1 , wherein the copy numbers are measured by comparative genomic hybridization (CGH).

8. The method of claim 1 , wherein the copy numbers are measured by next generation sequencing.

9. The method of claim 1 , wherein the biological sample is a tissue sample.

10. The method of claim 1 , wherein the sample is a fresh-frozen sample.

11. The method of claim 1 , wherein the sample is a fresh sample.

12. The method of claim 1 , wherein the sample is a fixed sample.

13. The method of claim 12 , wherein the fixed sample is a formalin-fixed, paraffin-embedded sample.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2017
From: BREEN, MATTHEW
To: NORTH CAROLINA STATE UNIVERSITY
Reel/Frame 041563/0442 →
Continuity (2)
Provisional Application 62028644 · Jul 24, 2014
Related Publication 20170211150A1 · Jul 27, 2017
Cited By (2)
US 12,188,094 US 12,297,504